Clinical trial

Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy

NCT06182800

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Adebrelimab Combined with Bevacizumab and Docetaxel Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2023-12-27

PhasePHASE2

Conditions

Non-small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Interventions

Adebrelimab Combined with Bevacizumab and DocetaxelDRUG

Sponsors & collaborators

The First Affiliated Hospital of Xinxiang Medical Collegelead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06182800 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.